J&J's Monistat 3 Rx-to-OTC switch approved by FDA; launch expected in early May.
This article was originally published in The Tan Sheet
OTC MONISTAT 3 WILL BE ON STORE SHELVES BY EARLY MAY, Johnson & Johnson subsidiary Advanced Care Products announced on April 23. FDA approved J&J's Rx-to-OTC switch application for the three-day miconazole nitrate vaginal yeast infection regimen on April 16. The launch of Monistat 3 Combination Pack will be accompanied by advertising campaigns targeted at both consumers and professionals, J&J said.
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC